EP300 and breast carcinoma: Moreover, high expression and activity of EP300 was demonstrated to be associated with various diseases and malignancies, including pulmonary fibrosis [46], nasopharyngeal carcinoma (NPC) [108], hepatocellular carcinoma (HCC) [109], non-small cell lung cancers (NSCLC) [110], prostate cancer (PCa) [111], and breast cancer (BC) [112].